Lung Cancer

A researcher suggests that understanding specific cell function in the tumor microenvironment can help create effective and individualized immunotherapy cancer treatments.

Selpercatinib is an oral selective RET kinase inhibitor approved for the treatment of metastatic RET fusion-positive non-small cell lung cancer and for metastatic thyroid cancer.

Results from the largest head-to-head trial of programmed death receptor-1 inhibitors suggest that dostarlimab and chemotherapy could be an effective treatment option for patients with metastatic non-squamous non-small cell lung cancer.

Despite significant advances in cancer treatment, molecular sequencing and enrollment of Black patients in clinical trials are still less than that of White and Asian patients.

Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Researchers at the European Society for Medical Oncology Congress presented findings that show osimertinib may clinically reduce the risk of lung cancer recurrence.

Trastuzumab deruxtecan produces a confirmed objective response rate of 53.8% and 42.9% in the 5.4 mg/kg arm and 6.4 mg/kg treatment arms, respectively, among patients with HER2 mutant non-small cell lung cancer.

An estimated 31.4% of individuals with non-squamous non–small cell lung cancer treated with the combination were alive at 3 years compared to 17.3% for those on chemotherapy alone.

Data presented at the 2022 ESMO congress show poziotinib has high activity in both treatment-naïve and previously treated patients with non-small cell lung cancer.

Data presented at the European Society for Medical Oncology Congress showed that sotorasib increased progression-free survival to 1 year in 25% of patients with KRAS G12C-mutated non-small cell lung cancer.

Sunvozertinib is an oral, potent EGFR exon20ins inhibitor with wild-type EGFR selectivity.

But the 2021 modifications to the US Preventive Services Task Force recommendations do not eliminate the inequalities, analysis shows.

Disease management is moving toward holistic care of the patient in the long term.

Atezolizumab meets its primary endpoint of overall survival for patients with resected non-small cell lung cancer across most subgroups.

Canakinumab did not meet the primary endpoint of disease-free survival in adult patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer.

The 4 academic centers will evaluate the role of telehealth in areas such as prevention, screening, diagnosis, treatment, and survivorship.

Long-term follow up on the KEYNOTE-604 study suggests pembrolizumab plus etoposide/platinum is a superior first-line therapy for small cell lung cancer vs placebo.

Irinotecan liposomal injection (Onivyde) used as second-line therapy for patients with small cell lung cancer did not meet the primary end point of overall survival compared to topotecan.

The Oncomine Dx Target Test is a next-generation sequencing–based companion diagnostic developed to analyze 23 genes associated with non–small cell lung cancer in patients who harbor an activating HER2 mutation.

A new study found that reduced tobacco use lowered deaths, person-years of lost life, and lost earnings across many states nationwide.

The FDA approval of fam-trastuzumab deruxtecan-nxki (Enhertu) to treat HER2 mutant non-small cell lung cancer was based on results from the DESTINY-Lung02 phase 2 trial.

The interim analysis of the TROPION-Lung02 trial demonstrate an overall response rate of 37% in individuals who were treated with datopotamab deruxtecan and pembrolizumab.

IMscin001 analysis shows non-inferior levels of the cancer immunotherapy in the blood compared with intravenous infusion in individuals with advanced non–small cell lung cancer.

Pharmacists have the potential to help optimize treatment and maximize supportive care management for targeted therapies.

Behavioral economics is a tool that can influence patient behaviors using concepts such as choice architecture, nudges, and loss aversion.

The findings of the phase 1b/2 CHRYSALIS-2 cohort will be presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer.

The FDA is evaluating the use of adagrasib (MRTX849) to treat patients with non-small cell lung cancer harboring a KRAS G12C mutation who have previously received at least 1 systemic therapy.

Poziotinib is an irreversible pan HER2 inhibitor with activity against mutations of HER1, HER2, and HER4.

Approximately one-third of the individuals had an intracranial response among those with central nervous system metastases.

Treatment's approval marks exciting new development for patients with ES-SCLC to prevent CIM.